KPIs & Operating Metrics(New)
Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
EBIATReceivables - NetReceivables - OtherReceivables Refunds
Ratios

Gsk (GSK) Non-Current Receivables (2016 - 2018)

Gsk (GSK) has 3 years of Non-Current Receivables data on record, last reported at $181.4 million in Q4 2018.

  • For Q4 2018, Non-Current Receivables fell 39.8% year-over-year to $181.4 million; the TTM value through Dec 2018 reached $181.4 million, down 39.8%, while the annual FY2018 figure was $188.3 million, 35.6% down from the prior year.
  • Non-Current Receivables reached $181.4 million in Q4 2018 per GSK's latest filing, down from $301.4 million in the prior quarter.
  • Across five years, Non-Current Receivables topped out at $353.1 million in Q4 2016 and bottomed at $181.4 million in Q4 2018.
  • Average Non-Current Receivables over 3 years is $278.6 million, with a median of $301.4 million recorded in 2017.
  • Peak YoY movement for Non-Current Receivables: decreased 14.64% in 2017, then crashed 39.8% in 2018.
  • A 3-year view of Non-Current Receivables shows it stood at $353.1 million in 2016, then dropped by 14.64% to $301.4 million in 2017, then crashed by 39.8% to $181.4 million in 2018.
  • Per Business Quant database, its latest 3 readings for Non-Current Receivables were $181.4 million in Q4 2018, $301.4 million in Q4 2017, and $353.1 million in Q4 2016.